Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024
For the Full year, the company expects revenue of $2,635 million to $2,735 million, net loss per share of $1,10 to $0.80.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.24 USD | -0.44% | -2.09% | -47.84% |
May. 21 | JPMorgan Adjusts Teladoc Price Target to $16 From $19, Maintains Neutral Rating | MT |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
1st Jan change | Capi. | |
---|---|---|
-47.84% | 1.91B | |
+78.57% | 584M | |
+3.15% | 445M | |
-71.35% | 127M | |
-25.18% | 94.34M |